23782 Federal Register / Vol. 75, No. 85 / Tuesday, May 4, 2010 / Notices 

Dated: April 28, 2010. 

Leslie Kux, 

Acting Assistant Commissioner for Policy. 

[FR Doc. 2010–10358 Filed 5–3–10; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Bariatric Surgery 

and Kidney Function. 

Date: June 8, 2010. 

Time: 2 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: D.G. Patel, PhD, Scientific 

Review Officer, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

756, 6707 Democracy Boulevard, Bethesda, 

MD 20892–5452, (301) 594–7682, 

pateldg@niddk.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Collaborative 

Interdisciplinary. 

Date: June 11, 2010. 

Time: 1 p.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications and/or proposals. 

Place: National Institutes of Health, Two 

Democracy Plaza, 6707 Democracy 

Boulevard, Bethesda, MD 20892 (Telephone 

Conference Call). 

Contact Person: D.G. Patel, PhD, Scientific 

Review Officer, Review Branch, DEA, 

NIDDK, National Institutes of Health, Room 

756, 6707 Democracy Boulevard, Bethesda, 

MD 20892–5452, (301) 594–7682, 

pateldg@niddk.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: April 27, 2010. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2010–10268 Filed 5–3–10; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Drug Safety and Risk Management 

Advisory Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Drug Safety and 

Risk Management Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on September 14, 2010, from 8 a.m. 

to 5 p.m. 

Location: The Marriott Inn and 

Conference Center, University of 

Maryland and University College 

(UMUC), The Ballrooms, 3501 

University Blvd. East, Adelphi, MD. The 

conference center telephone number is 

301–985–7300. 

Contact Person: Elaine Ferguson, email: elaine.ferguson@fda.hhs.gov 

(contact information through June 8, 

2010, Elaine Ferguson c/o Melanie 

Whelan, Food and Drug Administration, 

10903 New Hampshire Ave., WO51– 

6100, Silver Spring, MD 20993–0002, 

telephone: 301–827–7001, FAX: 301– 

847–8742), (contact information 

beginning June 9, 2010: Elaine Ferguson 

c/o Christine Shipe, Food and Drug 

Administration, 10903 New Hampshire 

Ave., WO31–2419, Silver Spring, MD 

20993–0002, telephone: 301–0796– 

9001, FAX: 301–847–8532), or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512535. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On September 14, 2010, the 

committee will discuss the abuse 

potential of the drug dextromethorphan 

and the public health benefits and risks 

of dextromethorphan use as a cough 

suppressant in prescription and 

nonprescription drug products. The 

Department of Health and Human 

Services received a request from the 

Drug Enforcement Administration for a 

scientific and medical evaluation and 

scheduling recommendation for 

dextromethorphan in response to the 

increased incidence of abuse, especially 

among adolescents. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before August 30, 2010. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. to 2 p.m. Those desiring to make 

formal oral presentations should notify 

the contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before August 20, 2010. Time allotted 

for each presentation may be limited. If 

the number of registrants requesting to 

speak is greater than can be reasonably 

accommodated during the scheduled 

open public hearing session, FDA may 

conduct a lottery to determine the 

speakers for the scheduled open public 

hearing session. The contact person will 

notify interested persons regarding their 

request to speak by August 23, 2010. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

mstockstill on DSKH9S0YB1PROD with NOTICES